Skip to Content
Stock Analyst Update

Lowering Our Gilead FVE to $75 After Q3

We have once again lowered our fair value estimate for Gilead, and now value the firm at $75 per share following third-quarter earnings.

Mentioned:

We have once again lowered our fair value estimate for Gilead (GILD) and now value the firm at $75 per share following third-quarter earnings. This follows a string of incrementally negative developments including the FDA complete response letter for immunology drug Jyseleca/filgotinib in August, a rich Immunomedics acquisition announcement in September, and the mid-October combination of a failed partnered (Galapagos) osteoarthritis therapy and disappointing further data for COVID-19 antiviral Veklury/remdesivir. While third-quarter results were roughly in line with our expectations, and Veklury demand remains in keeping with our relatively bearish expectations, we're reducing the probability of U.S. approval for Jyseleca to 50%, as Gilead acknowledged on the earnings call that the U.S. delay could turn into nonapprovability. We still think Gilead shares look slightly undervalued at recent prices, and we continue to think that Gilead's HIV portfolio and immunology and oncology pipelines warrant a wide moat rating. However, the firm is clearly in a transitional phase as it digests large oncology deals like Forty Seven and Immunomedics, and if these deals fail to generate blockbuster oncology therapies that allow Gilead to gain a foothold on the market, we could see some erosion of the firm's competitive advantages.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.